Загрузка...
Complete response with anti-PD-L1 antibody following progression on anti-PD-1 antibody in advanced non-small cell lung cancer
Immune-checkpoint inhibitors (ICI), specifically inhibitors of programmed death ligand-1 (PD-L1) and receptor (PD-1) are the new standard of care for the treatment of patients with advanced non-small cell lung cancer (NSCLC) in front line setting as monotherapy or along with chemotherapy. Many of th...
Сохранить в:
| Опубликовано в: : | BMJ Case Rep |
|---|---|
| Главные авторы: | , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BMJ Publishing Group
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7449356/ https://ncbi.nlm.nih.gov/pubmed/32843385 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2020-236101 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|